MX2024000690A - Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas. - Google Patents

Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas.

Info

Publication number
MX2024000690A
MX2024000690A MX2024000690A MX2024000690A MX2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
antibody
same
provides
enoblituzumab
Prior art date
Application number
MX2024000690A
Other languages
English (en)
Spanish (es)
Inventor
Yan Zhou
Stephen James Burke
Krishnan Sampathkumar
Xiaoyan Wang
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2024000690A publication Critical patent/MX2024000690A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2024000690A 2021-07-16 2022-07-06 Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas. MX2024000690A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
PCT/US2022/073462 WO2023288173A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Publications (1)

Publication Number Publication Date
MX2024000690A true MX2024000690A (es) 2024-02-07

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000690A MX2024000690A (es) 2021-07-16 2022-07-06 Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas.

Country Status (11)

Country Link
US (1) US20240336687A1 (https=)
EP (1) EP4370155A4 (https=)
JP (1) JP2024526773A (https=)
KR (1) KR20240038005A (https=)
CN (1) CN117715657A (https=)
AU (1) AU2022310668A1 (https=)
CA (1) CA3224118A1 (https=)
IL (1) IL310187A (https=)
MX (1) MX2024000690A (https=)
TW (1) TW202310874A (https=)
WO (1) WO2023288173A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2019246312A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
BR112022019073A2 (pt) * 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma

Also Published As

Publication number Publication date
CA3224118A1 (en) 2023-01-19
AU2022310668A1 (en) 2024-01-18
IL310187A (en) 2024-03-01
WO2023288173A1 (en) 2023-01-19
EP4370155A4 (en) 2025-06-11
JP2024526773A (ja) 2024-07-19
CN117715657A (zh) 2024-03-15
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
EP4370155A1 (en) 2024-05-22
TW202310874A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
EP4685160A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CR20220614A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
Bosco et al. Principles of antibiotic prophylaxis in total joint arthroplasty: current concepts
Shekarian et al. Paradigm shift in oncology: targeting the immune system rather than cancer cells
SA521430342B1 (ar) تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري
WO2019136300A3 (en) Anti-mct1 antibodies and uses thereof
Khan et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
McMillan et al. Antibody-drug conjugates for multiple myeloma
Rasche et al. Novel immunotherapies in multiple myeloma–chances and challenges
PH12020500205A1 (en) Anti-cd147 antibody
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
Parrondo et al. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
Van de Donk et al. S183: novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab
WO2022047047A8 (en) Inhalable therapeutic agents
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
WO2025117894A3 (en) Dimeric immunoconjugates for use in treating cancers and methods of use
MX2024000690A (es) Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas.
MX2023004533A (es) Formulaciones de anticuerpos anti-siglec-8.
Hosen Chimeric antigen receptor T-cell therapy for multiple myeloma
WO2022022464A8 (zh) 新型双特异性抗cd3/cd20多肽复合物配制剂
Verkleij et al. Immunotherapy in multiple myeloma: when, where, and for who?
WO2022023566A3 (en) Cd-3 antibodies for the treatment of coronavirus
MX2024000268A (es) Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas.
Polito et al. ATG‐saporin‐S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells
MX2025002839A (es) Combinacion farmaceutica y uso de la misma